Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.47 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.47 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | CTSL | P07711 | 2/20 | 0.45 |
| ▸ | CTSS | P25774 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24691336 | 1.00 | TAS1R3 (0.47) | TAS1R3TAS1R1CTSBCTSLCTSS | |
| SCHEMBL24691335 | 0.91 | TAS1R3 (0.48) | TAS1R3TAS1R1CTSBCTSLCTSS | |
| SCHEMBL26533686 | 0.91 | TAS1R3 (0.48) | TAS1R3TAS1R1CTSBCTSLCTSS | |
| SCHEMBL24690790 | 0.89 | CTSB (0.49) | TAS1R3TAS1R1CTSBCTSLCTSS | |
| SCHEMBL26533691 | 0.88 | CTSB (0.52) | TAS1R3TAS1R1CTSB | |
| SCHEMBL26233950 | 0.88 | CTSB (0.52) | TAS1R3TAS1R1CTSB | |
| SCHEMBL24691339 | 0.88 | TAS1R3 (0.47) | TAS1R3TAS1R1CTSBCTSLCTSS | |
| SCHEMBL24690792 | 0.88 | CTSB (0.52) | TAS1R3TAS1R1CTSB | |
| SCHEMBL26223640 | 0.88 | TAS1R3 (0.47) | TAS1R3TAS1R1CTSBCTSLCTSS | |
| SCHEMBL24691155 | 0.87 | TAS1R3 (0.55) | TAS1R3TAS1R1CTSBCTSLCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322668-A1 | PROTEASE INHIBITORS AS ANTIVIRALS | ACEA Therapeutics, Inc. (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230322668-A1 | PROTEASE INHIBITORS AS ANTIVIRALS | ACEA Therapeutics, Inc. (US) | 2023-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322668-A1 | PROTEASE INHIBITORS AS ANTIVIRALS | ACE, ACE2, TMPRSS15 | TAS1R3 1588/4885TAS1R1 1625/4885CTSB 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.